TerraPower Isotopes has shipped its first samples of Actinium-225 (Ac-225) to two pharmaceutical companies to develop targeted cancer treatments in drug trials.
Ac-225 is an alpha-emitting radionuclide that can be attached to a ligand that binds to cancer cells. Once delivered to patients, the isotope destroys cancerous tissue with minimum damage to nearby healthy cells, TerraPower said.
Global demand for Ac-225 is expected to increase as more radiopharmaceutical treatments using Actinium-225 are developed, the company noted.
